Stock Movers Closing Bell: ASML Surges, ImmunityBio Rallies, Constellation Energy Falls
Jan 16, 2026
Morgan Stanley pitches a bullish case for ASML, predicting a 70% rally as AI demand soars. ImmunityBio celebrates an 11-day stock surge following promising cancer trial results. On the flip side, Constellation Energy and other power producers tumble due to a new plan shifting costs to tech firms. Additionally, the market reacts to declining fertilizer demand, while DraftKings and Flutter struggle after disappointing sports betting revenues. Yields rise, defying expectations for lower rates.
AI Snips
Chapters
Transcript
Episode notes
ASML Seen As A Big AI Capex Beneficiary
- Morgan Stanley says ASML could rally as much as 70% if chipmakers keep boosting AI-related spending.
- ASML was up ~2% on the day and semiconductors outperformed with the Philly Semiconductor Index rising over 1%.
AST Space Mobile's Defense Win Spurs Rally
- AST Space Mobile jumped after winning prime contract position for the U.S. Missile Defense Agency's SHIELD program.
- The company is up ~60% year-to-date with 17% of its float sold short, driving volatile moves.
ImmunityBio Hits Record Rally After Trial News
- ImmunityBio (IBRX) extended an 11-session winning streak after reporting efficacy in a clinical cancer trial.
- The stock jumped nearly 40% that day and marked its best month since December 2019.